Literature DB >> 11713687

Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.

P V Bernhardt1, P Chin, D R Richardson.   

Abstract

Ligands of the 2-pyridylcarbaldehyde isonicotinoylhydrazone class show high iron (Fe) sequestering efficacy and have potential as agents for the treatment of Fe overload disease. We have investigated the mechanisms responsible for their high activity. X-ray crystallography studies show that the tridentate chelate 2-pyridylcarbaldehyde isonicotinoylhydrazone undergoes an unexpected oxidation to isonicotinoyl(picolinoyl)hydrazine when complexed with FeIII. In contrast, in the absence of FeIII, the parent hydrazone is not oxidized in aerobic aqueous solution. To examine whether the diacylhydrazine could be responsible for the biological effects of 2-pyridylcarbaldehyde isonicotinoylhydrazone, their Fe chelation efficacy was compared. In contrast to its parent hydrazone, the diacylhydrazine showed little Fe chelation activity. Potentiometric titrations suggested that this might be because the diacylhydrazine was charged at physiological pH, hindering its access across membranes to intracellular Fe pools. In contrast, the Fe complex of this diacylhydrazine was charge neutral, which may allow facile movement through membranes. These data allow a model of Fe chelation for this compound to be proposed: the parent aroylhydrazone diffuses through cell membranes to bind Fe and is subsequently oxidized to the diacylhydrazine complex which then diffuses from the cell. Other diacylhydrazine analogues that were charge neutral at physiological pH demonstrated high Fe chelation efficacy. Thus, for this class of ligands, the charge of the chelator appears to be an important factor for determining their ability to access intracellular Fe. The results of this study are significant for understanding the biological activity of 2-pyridylcarbaldehyde isonicotinoylhydrazone and for the design of novel diacylhydrazine chelators for clinical use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713687     DOI: 10.1007/s007750100258

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  9 in total

1.  Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.

Authors:  Paul V Bernhardt; Piao Chin; Philip C Sharpe; Jing-Yan C Wang; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2005-11-08       Impact factor: 3.358

2.  Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.

Authors:  Erika M Becker; David B Lovejoy; Judith M Greer; Ralph Watts; Des R Richardson
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

3.  Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues.

Authors:  Paul V Bernhardt; Lorraine M Caldwell; Timothy B Chaston; Piao Chin; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2003-10-15       Impact factor: 3.358

4.  Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands.

Authors:  Paul V Bernhardt; Gregory J Wilson; Philip C Sharpe; Danuta S Kalinowski; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2007-09-25       Impact factor: 3.358

5.  Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease.

Authors:  Timothy B Chaston; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2003-02-05       Impact factor: 3.358

6.  Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease.

Authors:  Carlos A Perez; Yong Tong; Maolin Guo
Journal:  Curr Bioact Compd       Date:  2008-10-01

7.  Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.

Authors:  Samantha Ellis; Danuta S Kalinowski; Lisa Leotta; Michael L H Huang; Peter Jelfs; Vitali Sintchenko; Des R Richardson; James A Triccas
Journal:  Mol Pharmacol       Date:  2013-11-15       Impact factor: 4.436

8.  Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats.

Authors:  Imir G Metushi; Tetsuya Nakagawa; Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2012-10-16       Impact factor: 3.739

9.  Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.

Authors:  Kar Kheng Yeoh; Mun Chiang Chan; Armin Thalhammer; Marina Demetriades; Rasheduzzaman Chowdhury; Ya-Min Tian; Ineke Stolze; Luke A McNeill; Myung Kyu Lee; Esther C Y Woon; Mukram M Mackeen; Akane Kawamura; Peter J Ratcliffe; Jasmin Mecinović; Christopher J Schofield
Journal:  Org Biomol Chem       Date:  2012-11-15       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.